Literature DB >> 15032789

An early- and late-stage convolution model for disease natural history.

Paul F Pinsky1.   

Abstract

The standard convolution model of disease natural history posits an asymptomatic (preclinical) and a symptomatic (clinical) state. An augmented model includes, in both the preclinical and clinical states, an early and late stage of disease. In the case of cancer, the early stage would generally correspond to the organ-confined stages before there is evidence of cancer spread. We compute the number of screen-detected (preclinical) and clinical cases in the early and late stages expected under a given screening program and show how the model can be fit to data from a screening trial using maximum likelihood. We also develop expressions for sojourn time, lead time, and overdiagnosis in the context of the model, where each of the above concepts incorporates disease stage. As an example, we fit the model to data from the Mayo Lung Cancer Screening trial.

Entities:  

Mesh:

Year:  2004        PMID: 15032789     DOI: 10.1111/j.0006-341X.2004.00023.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.

Authors:  Kevin Ten Haaf; Joost van Rosmalen; Harry J de Koning
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-13       Impact factor: 4.254

Review 2.  Missteps in Current Estimates of Cancer Overdiagnosis.

Authors:  Christoph I Lee; Ruth Etzioni
Journal:  Acad Radiol       Date:  2016-11-25       Impact factor: 3.173

3.  Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials.

Authors:  Marc D Ryser; Roman Gulati; Marisa C Eisenberg; Yu Shen; E Shelley Hwang; Ruth B Etzioni
Journal:  Am J Epidemiol       Date:  2019-01-01       Impact factor: 4.897

4.  Improving the biomarker pipeline to develop and evaluate cancer screening tests.

Authors:  Stuart G Baker
Journal:  J Natl Cancer Inst       Date:  2009-07-02       Impact factor: 13.506

Review 5.  Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.

Authors:  Jamie L Carter; Russell J Coletti; Russell P Harris
Journal:  BMJ       Date:  2015-01-07

Review 6.  [Lung Nodules Assessment--Analysis of Four Guidelines].

Authors:  Chunquan Liu; Yong Cui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-07-20

7.  Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review.

Authors:  Sandra M E Geurts; Anne M W M Aarts; André L M Verbeek; Tony H H Chen; Mireille J M Broeders; Stephen W Duffy
Journal:  Epidemiol Health       Date:  2022-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.